Gauckler, P;
Shin, JI;
Alberici, F;
Audard, V;
Bruchfeld, A;
Busch, M;
Cheung, CK;
... Kronbichler, A; + view all
(2021)
Rituximab in Membranous Nephropathy.
Kidney International Reports
10.1016/j.ekir.2020.12.035.
(In press).
Preview |
Text
Salama_Rituximab in Membranous Nephropathy_AOP.pdf - Published Version Download (713kB) | Preview |
Abstract
Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard.”
| Type: | Article |
|---|---|
| Title: | Rituximab in Membranous Nephropathy |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ekir.2020.12.035 |
| Publisher version: | http://dx.doi.org/10.1016/j.ekir.2020.12.035 |
| Language: | English |
| Additional information: | © 2021 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | B cells, membranous nephropathy, nephrotic syndrome, rituximab |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10125429 |
Archive Staff Only
 |
View Item |
